SCHEMBL5163582

SCHEMBL5163582

CCN(C(=O)c1c(O)c2c(Br)cccc2n(C)c1=O)c1ccccc1

nearest known ligand 0.49

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 6/20 0.49
KMT2A Q03164 6/20 0.49
PGR P06401 1/20 0.49
HDAC4 P56524 1/20 0.42
ALDH1A1 P00352 3/20 0.40
KDM4E B2RXH2 2/20 0.40
TSHR P16473 2/20 0.40
GLA P06280 1/20 0.40
TP53 P04637 1/20 0.39
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38
MAP3K5 Q99683 1/20 0.38
POLB P06746 2/20 0.38
PABPC1 P11940 2/20 0.38
MAPT P10636 2/20 0.38
GAA P10253 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15190559 0.89 MEN1 (0.51) MEN1KMT2APGRHDAC4ALDH1A1
Paquinimod SCHEMBL1573633 0.88 MEN1 (0.50) MEN1KMT2APGRHDAC4ALDH1A1
SCHEMBL5164257 0.88 MEN1 (0.50) MEN1KMT2APGRHDAC4ALDH1A1
Paquinimod SCHEMBL29362498 0.88 MEN1 (0.50) MEN1KMT2APGRHDAC4ALDH1A1
Paquinimod SCHEMBL1573731 0.87 MEN1 (0.49) MEN1KMT2APGRHDAC4ALDH1A1
SCHEMBL15958573 0.87 MEN1 (0.49) MEN1KMT2APGRHDAC4ALDH1A1
Laquinimod SCHEMBL29438575 0.87 TP53 (0.50) MEN1KMT2APGRHDAC4ALDH1A1
Paquinimod SCHEMBL1573462 0.87 MEN1 (0.49) MEN1KMT2APGRHDAC4ALDH1A1
Paquinimod SCHEMBL1573653 0.87 MEN1 (0.49) MEN1KMT2APGRHDAC4ALDH1A1
Laquinimod SCHEMBL39440 0.87 TP53 (0.50) MEN1KMT2APGRHDAC4ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1224172-B1 DRUGS FOR THE TREATMENT OF MALIGNANT TUMOURS ACTIVE BIOTECH AB (SE) 2007-04-04 EP claimed
EP-1073639-B1 QUINOLINE DERIVATIVES ACTIVE BIOTECH AB (SE) 2002-11-27 EP claimed
US-6395750-B1 Includes laquinimod, N-ethyl-N-phenyl-1,2-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxo-quinoline-3-carboxamide and its salts; breat or prostate cancer ACTIVE BIOTECH AB (SE) 2002-05-28 US claimed
EP-1073639-A1 QUINOLINE DERIVATIVES Active Biotech AB (SE) 2001-02-07 EP claimed
US-6077851-A USED FOR TREATMENT OF DISEASES RESULTING FROM AUTOIMMUNITY SUCH AS MULTIPLE SCLEROSIS, INSULIN-DEPENDENT DIABETES MELLITUS, SYSTEMIC LUPUS ERYTHEMATOSUS, RHEUMATOID ARTHRITIS, INFAMMATORY BOWEL DISEASE AND PSORIASIS; LAQUINIMOD AS NEW CHEMICAL ENTITY ACTIVE BIOTECH AB (SE) 2000-06-20 US claimed
WO-1999055678-A1 QUINOLINE DERIVATIVES ACTIVE BIOTECH AB (SE) 1999-11-04 WO claimed
EP-1224172-B1 DRUGS FOR THE TREATMENT OF MALIGNANT TUMOURS ACTIVE BIOTECH AB (SE) 2007-04-04 EP disclosed
EP-1073639-B1 QUINOLINE DERIVATIVES ACTIVE BIOTECH AB (SE) 2002-11-27 EP disclosed
US-6395750-B1 Includes laquinimod, N-ethyl-N-phenyl-1,2-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxo-quinoline-3-carboxamide and its salts; breat or prostate cancer ACTIVE BIOTECH AB (SE) 2002-05-28 US disclosed
EP-1073639-A1 QUINOLINE DERIVATIVES Active Biotech AB (SE) 2001-02-07 EP disclosed
US-6077851-A USED FOR TREATMENT OF DISEASES RESULTING FROM AUTOIMMUNITY SUCH AS MULTIPLE SCLEROSIS, INSULIN-DEPENDENT DIABETES MELLITUS, SYSTEMIC LUPUS ERYTHEMATOSUS, RHEUMATOID ARTHRITIS, INFAMMATORY BOWEL DISEASE AND PSORIASIS; LAQUINIMOD AS NEW CHEMICAL ENTITY ACTIVE BIOTECH AB (SE) 2000-06-20 US disclosed
WO-1999055678-A1 QUINOLINE DERIVATIVES ACTIVE BIOTECH AB (SE) 1999-11-04 WO disclosed